Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.12.2022 | Case report

Multiple drugs

Various toxicities and development of drug resistance: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Zhang LD, et al. Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases. Anti-Cancer Drugs 33: e486-e490, No. 1, Jan 2022. Available from: URL: http://doi.org/10.1097/CAD.0000000000001148 Zhang LD, et al. Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases. Anti-Cancer Drugs 33: e486-e490, No. 1, Jan 2022. Available from: URL: http://​doi.​org/​10.​1097/​CAD.​0000000000001148​
Metadaten
Titel
Multiple drugs
Various toxicities and development of drug resistance: 2 case reports
Publikationsdatum
01.12.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-29122-4

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs